Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Dongzheng Gai, MD, Stewart JP, Xuxing Shen, Jin-Ran Chen, PhD, Can Li, MD, Bailu Peng, PhD, Ya-Wei Qiang, MD PhD, Shmuel Yaccoby, PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Guido J. Tricot, MD PhD, Lijuan Chen, MDPhD, John Shaughnessy, Jr., PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140568

Published: 2020

Journal Articles

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Xuelian Tan, Timothy Cody Ashby, PhD, Yuqi Zhu, Can Li, MD, Xuxing Shen, MBBS, Qierra Brockman, BA, Dongzheng Gai, MD, Sarah K Johnson, PhD, Donghoon Yong, Carolina D. Schinke, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, John Shaughnessy, Jr., PhD, Dingming Huang, PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140372

Published: 2020

Journal Articles

N-Cadherin Expressing MM Cells Form Calcium-Dependent, Adherent Junctions That Likely Contribute to Focal Lesions and Nodular Growth of Multiple Myeloma Cells

Ya-Wei Qiang, MD, PhD, Bo Hu, Yu Chen, Erming Tian, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, John Shaughnessy, Jr, PhD

Blood (2010) 116 (21): 979.

https://doi.org/10.1182/blood.V116.21.979.979

Published: 2010

Journal Articles

Systemically Injected Mesenchymal Stem Cells Traffic to Myelomatous Bone and Inhibit Bone Disease, and Intralesionally Promotes Bone Formation and Delays Myeloma Progression During the Disease Active Stage or Remission

Xin Li, PhD, Wen Ling, MS, Sharmin Khan, MS, Yuping Wang, PhD, Angela Pennisi, MD, Bart Barlogie, MD, PhD, John Shaughnessy, Jr, PhD, Shmuel Yaccoby, PhD

Blood (2010) 116 (21): 980.

https://doi.org/10.1182/blood.V116.21.980.980

Published: 2010

Journal Articles

Human Placenta-Derived Adherent Cells Delivered Intralesionally Inhibit Myeloma Bone Disease and Tumor Growth, While Intravenously Are Capable of Trafficking to Myelomatous Bone.

Xin Li, PhD, Wen Ling, MS, Angela Pennisi, MD, Yuping Wang, PhD, Sharmin Khan, MS, Mohammad Heidaran, PhD, Ajai Pal, PhD, Xiaokui Zhang, PhD, Shuyang He, PhD, Andy Zeitlin, Stewart Abbot, PhD, Herbert Faleck, DO, Robert Hariri, MD, PhD., John Shaughnessy, Jr., PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, MPH, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD

Blood (2010) 116 (21): 3717.

https://doi.org/10.1182/blood.V116.21.3717.3717

Published: 2010

Journal Articles

Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease

Rakesh Bam, Angela Pennisi, MD, Xin Li, PhD, Sharmin Khan, MS, Yuping Wang, Ph.D., Wen Ling, MS, Bart Barlogie, M.D., Ph.D., John Shaughnessy, Jr., PhD, Shmuel Yaccoby, PhD

Blood (2010) 116 (21): 447.

https://doi.org/10.1182/blood.V116.21.447.447

Published: 2010

Journal Articles

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Unn-Merete Fagerli, MD, PhD, Thorsten Stühmer, PhD, Toril Holien, Randi Utne Holt, PhD, Ove Bruland, PhD, Manik Chatterjee, MD, John Shaughnessy, Jr, PhD, Stephan Mathas, MD, Anders Sundan, MD, Ralf C Bargou, MD, Bernd Dörken, MD, Magne Borset, MD, PhD, Martin Janz, MD

Blood (2010) 116 (21): 1915.

https://doi.org/10.1182/blood.V116.21.1915.1915

Published: 2010

Journal Articles

DKK1 is an Immediate Early Gene in Multiple Myeloma Cells Modulated by Cell Density and IL-6

Erming Tian, PhD, Yawei Qiang, MD, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, Jr, PhD

Blood (2010) 116 (21): 1928.

https://doi.org/10.1182/blood.V116.21.1928.1928

Published: 2010

Journal Articles

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

Madhav Dhodapkar, MD, MBBS, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, Bijay Nair, MD, MPH, Vanessa Bolejack, Frits van Rhee, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1932.

https://doi.org/10.1182/blood.V116.21.1932.1932

Published: 2010

Journal Articles

Systemically Transplanted Human Bone Marrow Mesenchymal Stem Cells Primarily Traffic to Mesenteric Lymph Nodes

Xin Li, PhD, Wen Ling, MS, Sharmin Khan, MS, Yuping Wang, Ph.D., Angela Pennisi, MD, Bart Barlogie, MD, PhD, John Shaughnessy, Jr., PhD, Shmuel Yaccoby, PhD

Blood (2010) 116 (21): 2580.

https://doi.org/10.1182/blood.V116.21.2580.2580

Published: 2010

Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Jackie Szymonifka, Elias J. Anaissie, MD, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, John Crowley, PhD

Blood (2010) 116 (21): 1356.

https://doi.org/10.1182/blood.V116.21.1356.1356

Published: 2010

Journal Articles

Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma

Jayakumar Nair, Ph.D., Louise Carlson, Cheryl H Rozanski, BS, Chandana Koorella, Megan Murray, John Shaughnessy, Jr., PhD, P.Leif Bergsagel, MD, Lawrence H. Boise, PhD, Asher A. Chanan-Khan, Kelvin P Lee, MD

Blood (2010) 116 (21): 132.

https://doi.org/10.1182/blood.V116.21.132.132

Published: 2010

Journal Articles

Abnormally High Levels of E- and N-Cadherin Expression Add to Altered Regulation of b-Catenin In Multiple Myeloma

Ya-Wei Qiang, MD, PhD, Peter Stewart, PhD, Yu Chen, Bo Hu, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 2982.

https://doi.org/10.1182/blood.V116.21.2982.2982

Published: 2010

Journal Articles

Loss of Chemokine Receptor Expression and Tetraspanins Is Correlated with Extramedullary Disease In Multiple Myeloma

Zeba N Singh, MD, Rebecca B Owens, BSMT, Bijay Nair, MD, MPH, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 2983.

https://doi.org/10.1182/blood.V116.21.2983.2983

Published: 2010

Journal Articles

Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols

Pingping Qu, Jeff Haessler, John Shaughnessy, Jr., PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 2985.

https://doi.org/10.1182/blood.V116.21.2985.2985

Published: 2010

Journal Articles

Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4

John Shaughnessy, Jr., PhD, Pingping Qu, Erming Tian, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Frits van Rhee, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 303.

https://doi.org/10.1182/blood.V116.21.303.303

Published: 2010

Journal Articles

Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival

Igor Entin, PhD, Shmuel Yaccoby, PhD, Wen Zhining, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc

Blood (2010) 116 (21): 2957.

https://doi.org/10.1182/blood.V116.21.2957.2957

Published: 2010

Journal Articles

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Jumei Shi, MD, PhD, Susann Szmania, BS, Guido Tricot, MD, PhD, Tarun K. Garg, PhD, Priyangi A Malaviarachchi, BS, Amberly Moreno-Bost, BS, Katie Stone, BS, Fenghuang Zhan, MD, PhD, Dario Campana, MD, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 2758.

https://doi.org/10.1182/blood.V112.11.2758.2758

Published: 2008

Journal Articles

Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103

Amberly Moreno-Bost, BS, Susann Szmania, BS, Katie Stone, BS, Jumei Shi, MD, PhD, Tarun K. Garg, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Hugh Grant Prentice, MD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 3674.

https://doi.org/10.1182/blood.V112.11.3674.3674

Published: 2008

Journal Articles

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Brian G.M. Durie, MD, Brian Van Ness, PhD, Christine Ramos, PhD, Owen Stephens, Majda Haznadar, Antje Hoering, PhD, Jeff Haessler, PhD, Michael S. Katz, BS, Gregory R. Mundy, MD, Robert A. Kyle, MD, Gareth J. Morgan, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, John Shaughnessy, Jr., PhD

Blood (2007) 110 (11): 816.

https://doi.org/10.1182/blood.V110.11.816.816

Published: 2007

NARROW

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

N-Cadherin Expressing MM Cells Form Calcium-Dependent, Adherent Junctions That Likely Contribute to Focal Lesions and Nodular Growth of Multiple Myeloma Cells

Systemically Injected Mesenchymal Stem Cells Traffic to Myelomatous Bone and Inhibit Bone Disease, and Intralesionally Promotes Bone Formation and Delays Myeloma Progression During the Disease Active Stage or Remission

Human Placenta-Derived Adherent Cells Delivered Intralesionally Inhibit Myeloma Bone Disease and Tumor Growth, While Intravenously Are Capable of Trafficking to Myelomatous Bone.

Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

DKK1 is an Immediate Early Gene in Multiple Myeloma Cells Modulated by Cell Density and IL-6

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

Systemically Transplanted Human Bone Marrow Mesenchymal Stem Cells Primarily Traffic to Mesenteric Lymph Nodes

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma

Abnormally High Levels of E- and N-Cadherin Expression Add to Altered Regulation of b-Catenin In Multiple Myeloma

Loss of Chemokine Receptor Expression and Tetraspanins Is Correlated with Extramedullary Disease In Multiple Myeloma

Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols

Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4

Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only